leadf
logo-loader
viewANGLE PLC

ANGLE’s Parsortix to be in focus at AACC annual meeting

Parsortix will be in focus of experts later today at the AACC meeting.

blood vials
Parsortix can capture cancer cells in blood for analysis.

ANGLE PLC’s (OTCMKTS:ANPCY, LON:AGL) Parsortix device will be the focus of a poster presentation at the American Association for Clinical Chemistry (AACC) annual meeting later today.

Posters are used at large conventions such as the AACC to showcase discoveries or developments.

In the case of ANGLE it will be used to demonstrate Parsortix’s ability to harvest breast cancer cells for subsequent gene expression analysis.

The presentation is based around the pioneering work of James Reuben, a professor at the University of Texas MD Anderson Cancer Center.

According to ANGLE chief technology officer, Shane Booth, gene expression analysis could prove a “very important” new diagnostic tool.

Quick facts: ANGLE PLC

Price: 48.5 GBX

AIM:AGL
Market: AIM
Market Cap: £83.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Angle’s Newland reflects on excellent year as cancer patient trials advance

Angle Plc (LON:AGL, OTCMKTS:ANPCY) is poised to revolutionise cancer treatment with its Parsortix system, here we catch up with chief executive Andrew Newland. As Newland explains Parsortix can capture cancer cells from blood, which is very significant for the emerging field of...

on 07/28/2016

2 min read